August 12, 2024 by Elana Gotkine Dupilumab maintains its effectiveness up to five years in patients with eczemaFor patients with atopic dermatitis (AD), dupilumab maintains its clinical effectiveness up to five years and is discontinued by 23.8% of patients, according to a study published online Aug. 7 in JAMA Dermatology. Celeste M. Boesjes, M.D., from...
Tag: <span>Dupilumab</span>
Post
Lymphoid reaction observed in eczema patients receiving dupilumab
by Elana Gotkine For adults with atopic dermatitis (AD) receiving dupilumab treatment, a reversible lymphoid reaction (LR) has been observed, which mimics cutaneous T-cell lymphoma (CTCL), according to a study published online Oct. 18 in JAMA Dermatology. Celeste M. Boesjes, M.D., from the University Medical Center Utrecht in the Netherlands, and colleagues conducted a retrospective...
Post
Dupilumab found to lessen disease in COPD patients with type 2 inflammation
by Jeff Hansen, University of Alabama at Birmingham Credit: Pixabay/CC0 Public Domain Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements in their disease after treatment with the monoclonal antibody dupilumab, according to a yearlong, Phase 3 clinical trial reported in the New England Journal of Medicine. These improvements—as measured by a significantly lower...
Post
Dupilumab Curbs Acute COPD Exacerbations
Heidi Splete May 22, 2023 Dupilumab significantly reduced exacerbations in adults with chronic obstructive pulmonary disease by approximately 30% compared with placebo, based on data from approximately 900 individuals. Chronic obstructive pulmonary disease (COPD) is associated with decreased lung function and increased risk of exacerbations, and previous studies of anti-interleukin-5 biologics have yielded mixed results, according to...